101 related articles for article (PubMed ID: 19786142)
1. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis.
Guan Q; Ma Y; Hillman CL; Ma A; Zhou G; Qing G; Peng Z
Vaccine; 2009 Nov; 27(50):7096-104. PubMed ID: 19786142
[TBL] [Abstract][Full Text] [Related]
2. Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis.
Guan Q; Burtnick HA; Qing G; Weiss CR; Ma AG; Ma Y; Warrington RJ; Peng Z
Immunotherapy; 2013 Dec; 5(12):1313-22. PubMed ID: 24283842
[TBL] [Abstract][Full Text] [Related]
3. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis.
Guan Q; Ma Y; Hillman CL; Qing G; Ma AG; Weiss CR; Zhou G; Bai A; Warrington RJ; Bernstein CN; Peng Z
Mol Med; 2011; 17(7-8):646-56. PubMed ID: 21424108
[TBL] [Abstract][Full Text] [Related]
4. An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo.
Guan Q; Weiss CR; Qing G; Ma Y; Peng Z
Immunotherapy; 2012 Dec; 4(12):1799-807. PubMed ID: 23240747
[TBL] [Abstract][Full Text] [Related]
5. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M
Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
7. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice.
Ma Y; Hayglass KT; Becker AB; Halayko AJ; Basu S; Simons FE; Peng Z
Allergy; 2007 Jun; 62(6):675-82. PubMed ID: 17508973
[TBL] [Abstract][Full Text] [Related]
8. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice.
Ma Y; HayGlass KT; Becker AB; Fan Y; Yang X; Basu S; Srinivasan G; Simons FE; Halayko AJ; Peng Z
Am J Respir Crit Care Med; 2007 Sep; 176(5):439-45. PubMed ID: 17556715
[TBL] [Abstract][Full Text] [Related]
9. IL-10 gene therapy prevents TNBS-induced colitis.
Lindsay J; Van Montfrans C; Brennan F; Van Deventer S; Drillenburg P; Hodgson H; Te Velde A; Sol Rodriguez Pena M
Gene Ther; 2002 Dec; 9(24):1715-21. PubMed ID: 12457286
[TBL] [Abstract][Full Text] [Related]
10. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.
Stallmach A; Marth T; Weiss B; Wittig BM; Hombach A; Schmidt C; Neurath M; Zeitz M; Zeuzem S; Abken H
Gut; 2004 Mar; 53(3):339-45. PubMed ID: 14960512
[TBL] [Abstract][Full Text] [Related]
11. The bile acid receptor FXR is a modulator of intestinal innate immunity.
Vavassori P; Mencarelli A; Renga B; Distrutti E; Fiorucci S
J Immunol; 2009 Nov; 183(10):6251-61. PubMed ID: 19864602
[TBL] [Abstract][Full Text] [Related]
12. [Suppression of Schistosoma japonicum eggs on TNBS-induced colitis in mice].
Mo HM; Liu WQ; Lei JH; Cheng YL; Wang CZ; Li YL
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Oct; 25(5):381-4. PubMed ID: 18441989
[TBL] [Abstract][Full Text] [Related]
13. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis.
Ma Y; Guan Q; Bai A; Weiss CR; Hillman CL; Ma A; Zhou G; Qing G; Peng Z
Inflamm Bowel Dis; 2010 Jun; 16(6):1040-50. PubMed ID: 19924805
[TBL] [Abstract][Full Text] [Related]
14. Reversing Ongoing Chronic Intestinal Inflammation and Fibrosis by Sustained Block of IL-12 and IL-23 Using a Vaccine in Mice.
Guan Q; Weiss CR; Wang S; Qing G; Yang X; Warrington RJ; Bernstein CN; Peng Z
Inflamm Bowel Dis; 2018 Aug; 24(9):1941-1952. PubMed ID: 29788053
[No Abstract] [Full Text] [Related]
15. Targeting IL-23 by employing a p40 peptide-based vaccine ameliorates murine allergic skin and airway inflammation.
Guan Q; Ma Y; Aboud L; Weiss CR; Qing G; Warrington RJ; Peng Z
Clin Exp Allergy; 2012 Sep; 42(9):1397-405. PubMed ID: 22925326
[TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
[TBL] [Abstract][Full Text] [Related]
18. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
19. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
20. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis.
Fichtner-Feigl S; Young CA; Kitani A; Geissler EK; Schlitt HJ; Strober W
Gastroenterology; 2008 Dec; 135(6):2003-13, 2013.e1-7. PubMed ID: 18938165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
